NCT00867113 · OUTCOME
Kaplan-Meier Estimates for Recurrence-free Survival up to 60 Months
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) · Source last updated 2018-03-14
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of patients
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Baseline up to 60 months
What was measured
Recurrence-free survival (RFS) assessment is based on the radiologic evidence and is defined as the time from the date of first dose of imatinib to the date of the first documented disease recurrence or death due to any cause (event). RFS estimates were summarized using the Kaplan-Meier product-limit method (Kaplan 1958). Censoring rules for RFS with the earliest occurring rule used in the analysis: subjects without objective recurrence of disease who were alive at the time of their discontinuation from study were censored at the end of study date or end of treatment visit date if the subject refused to be followed post treatment and subjects recording antineoplastic therapy during the study were censored on the date of the therapy initiated
Groups in this outcome
Imatinib
All subjects received in tablet form imatinib (STI571) 400 mg once daily.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Imatinib | 91 |
|---|
Reported measurements
12 months
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Imatinib | 97.7 | Not reported | 91.1 | 99.4 | Not reported |
|---|
18 months
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Imatinib | 97.7 | Not reported | 91.1 | 99.4 | Not reported |
|---|
24 months
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Imatinib | 96.5 | Not reported | 89.6 | 98.9 | Not reported |
|---|
36 months
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Imatinib | 95.1 | Not reported | 87.5 | 98.2 | Not reported |
|---|
48 months
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Imatinib | 95.1 | Not reported | 87.5 | 98.2 | Not reported |
|---|
60 months
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Imatinib | 90.1 | Not reported | 80.0 | 95.2 | Not reported |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 91.1
- upper Limit
- 99.4
- value
- 97.7
- title
- 12 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 91.1
- upper Limit
- 99.4
- value
- 97.7
- title
- 18 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 89.6
- upper Limit
- 98.9
- value
- 96.5
- title
- 24 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 87.5
- upper Limit
- 98.2
- value
- 95.1
- title
- 36 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 87.5
- upper Limit
- 98.2
- value
- 95.1
- title
- 48 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 80.0
- upper Limit
- 95.2
- value
- 90.1
- title
- 60 months
- description
- Recurrence-free survival (RFS) assessment is based on the radiologic evidence and is defined as the time from the date of first dose of imatinib to the date of the first documented disease recurrence or death due to any cause (event). RFS estimates were summarized using the Kaplan-Meier product-limit method (Kaplan 1958). Censoring rules for RFS with the earliest occurring rule used in the analysis: subjects without objective recurrence of disease who were alive at the time of their discontinuation from study were censored at the end of study date or end of treatment visit date if the subject refused to be followed post treatment and subjects recording antineoplastic therapy during the study were censored on the date of the therapy initiated
- dispersion Type
- 95% Confidence Interval
- groups
- description
- All subjects received in tablet form imatinib (STI571) 400 mg once daily.
- id
- OG000
- title
- Imatinib
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- Baseline up to 60 months
- title
- Kaplan-Meier Estimates for Recurrence-free Survival up to 60 Months
- type
- PRIMARY
- unit Of Measure
- percentage of patients
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle